期刊
GASTROENTEROLOGIA Y HEPATOLOGIA
卷 41, 期 5, 页码 328-349出版社
ELSEVIER ESPANA SLU
DOI: 10.1016/j.gastrohep.2017.12.003
关键词
Non-alcoholic fatty liver disease; Diagnosis; Treatment; Clinical guidelines; Recommendations; Steatosis; Fibrosis; Cardiovascular risk
Non-alcoholic fatty liver disease (NAFLD) is the main cause of liver diseases in Spain and the incidence is raising due to the outbreak of type 2 diabetes and obesity. This CPG suggests recommendation about diagnosis, mainly non-invasive biomarkers, and clinical management of this entity. Life-style modifications to achieve weight toss is the main target in the management of NAFLD. Low caloric Mediterranean diet and 200 minutes/week of aerobic exercise are encouraged. In non-responders patients with morbid obesity, bariatric surgery or metabolic endoscopy could be indicated. Pharmacological therapy is indicated in patients with NASH and fibrosis and non-responders to weight loss measures. NAFLD could influence liver transplantation, as a growing indication, the impact of steatosis in the graft viability, de novo NAFLD rate after OLT and a raised cardiovascular risk that modify the management of this entity. The current CPG was the result of the First Spanish NAFLD meeting in Seville. (C) 2018 Elsevier Espana, S.L.U. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据